Good Intelligence Platform |AI for Pharma RegIntel

AI agents that monitor FDA/EMA/PMDA updates and draft compliant pharma documents. Regulatory intelligence meets document automation. 🧬🤖

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

@DrDatta_AIIMS This is what we’re doing with https://t.co/TBYqrOIx35

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

$NVO This could have been prevented! https://t.co/8fqr2w0n6L

[Adam Feuerstein ✡️ @adamfeuerstein]

FDA declares Novo Nordisk $NVO (Catalent) plant, key to drug manufacturing for some biotechs, out of compliance. Impacting $SRRK and $REGN today.

https://t.co/LLlei1xM7X via @elaineywchen

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

If you think this is bad, think about how difficult it is for multiple disciplines to agree on simple document updates… https://t.co/TBYqrOIx35

[Healthcare AI Guy @HealthcareAIGuy]

Admin costs in healthcare are growing at a faster pace than direct patient care costs

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

We interviewed 50+ regulatory affairs professionals at pharmaceutical companies.

The #1 pain point mentioned by 82%:

"We spend weeks manually updating SOPs and batch records every time FDA publishes new guidance."

This work should be automated.

We're making it happen.

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

The ROI for AI drug discovery is still TBD… but the ROI for document management is evident.

[Yair Einhorn @yaireinhorn]

1/🚨WOW! CRISPR & Gene Editing have made it into today’s FT’s business section After AstraZeneca’s announced its recent $555M collaboration signed with Algen Bio - a Berkeley-based company which originated from the lab of CRISPR co-inventor and Nobel Prize winner Jennifer Doudna.

According to the collaboration agreement- $AZN will receive certain rights to develop and commercialise CRISPR Gene Editing therapies and Algen will receive in return $555M upon achieving specific commercial and regulatory milestones.

It’s always a positive sign when Big Pharma companies are returning and reinvesting in the CRISPR & Gene Editing space. $XBI

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

@ohodgex @parmita Even more so in biopharmaceutical manufacturing

[Parmita Mishra @parmita]

saying AI in biology is a scam is more about your lack of understanding of its strengths and limitations. It is quite like saying computers in biology are a scam.

The 2 simplest ways AI helps biology
- parsing multimodal data in parallel to choose the best data for a human to look at reducing inefficiency
- ability to embed large numbers of signals about cells and clusters of cells to create lower-dimensional representations that are more human interpretable in the 3D/4D.

Even people who think AI in biology is a grift (lol) cannot argue against these two.

If you think AI is a scam here, that is either a data issue or a skill issue.

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

How AI agents actually monitor regulatory changes:

1. Web scrapers check https://t.co/jNfE2wIcXj, EMA, PMDA every 6 hours
2. NLP models detect semantic changes in guidance
3. RAG retrieves affected sections from your documents
4. LLM drafts compliant revisions with citations
5. Human reviews and approves

Agentic AI in production. Check us out https://t.co/DlOd6okesT

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

The ROI from AI in healthcare will be astounding.

[Dr Singularity @Dr_Singularity]

Everything is accelerating

Researchers at Harvard Medical School developed a tool that uses AI to accelerate drug discovery and development.

"The new technology, called PDGrapher, applies machine learning to identify a list of genes that can reverse disease in cells when targeted by drugs."

"The study, published last month in Nature, claims the technology works up to 25 times faster than existing methods."

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

AI continues to understand Health as biology is a #languagescience

[Genetic Engineering & Biotechnology News @GENbio]

ChatGPT-Like AI Model Details 1,300 Regions/Subregions in Mouse Brain Map

Tissue-agnostic CellTransformer can be used on other organs and tissues, including cancerous tissue, for which large-scale #spatialtranscriptomics data is available
@UCSF
#brain #AI
https://t.co/nlCaOt1lfY

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

@mark_k Is the context window larger than my physicians memory?

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

@bindureddy Agreed, we’re actually getting rid of tedious activities and building a true foundation of intelligence for pharma companies. Check us out! https://t.co/p5cIj8PRNs

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

@AndrewE_Dunn AI implemented effectively across all heavily regulated industries will be one of the largest benefits for humanity

[Craig Weiss @craigweiss]

Wealth in tech isn’t created. It’s transferred from those who ship slowly to those who ship quickly.

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

We interviewed 50+ regulatory affairs professionals at pharmaceutical companies.

The #1 pain point mentioned by 82%:

"We spend weeks manually updating SOPs and batch records every time FDA publishes new guidance."

This work should be automated.

We're making it happen.

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

The regulatory compliance cost breakdown for mid-market pharma:

[Create simple chart showing:]
• Manual labor: $850K/year
• Regulatory intelligence tools: $450K/year
• Document management: $350K/year
Total: $1.65M/year

With automation: $200-350K/year

The ROI is undeniable. 📊

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

@yaireinhorn Wow, this $NVO-$AKRO deal is a game-changer! $54/share + $6 CVR ($5.2B total) for efruxifermin’s MASH potential is bold under new CEO Mike Doustdar’s watch [Reuters, 10/09]. With 29% fibrosis improvement at 96 weeks in Phase IIb [Applied Clinical Trials, 10/05] and MASH cases set to double by 2030 [Frontiers, 2024], this could redefine Novo’s metabolic portfolio. Thoughts on the 9,000 job cuts’ impact? $XBI

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

@HealthcareAIGuy @JAMANetwork This administrative burden doesn’t only exist at the clinical level, but also within the pharmaceutical companies themselves! The “validation tax” is growing exponentially

[Healthcare AI Guy @HealthcareAIGuy]

If you're in Philly, come hang out in November!

Join @davidwest_irl, CEO/Founder of @Proscia, and others (TBA...) — we’ll have a panel of founders, investors, & a crowd of builders, execs, and enthusiasts.

If you are interested in sponsoring and/or speaking, let us know ⚡

[Good Intelligence Platform |AI for Pharma RegIntel @reg_tech_ai]

How AI agents actually monitor regulatory changes:

1. Web scrapers check https://t.co/jNfE2wIcXj, EMA, PMDA every 6 hours
2. NLP models detect semantic changes in guidance
3. RAG retrieves affected sections from your documents
4. LLM drafts compliant revisions with citations
5. Human reviews and approves

Agentic AI in production.